Gilteritinib is an orally administered, second generation, highly selective type I FLT3 inhibitor with potent activity against both FLT3 subtypes (ITD and TKD). It also inhibits several other kinases, including AXL, which has been implicated in FLT3 inhibitor resistance, c-KIT, and anaplastic lymphoma kinase (ALK).